Tallying Up the Dx Score Card
Executive Summary
An overview of the diagnostics industry's year-to-date performance is not inspiring. Total industry sales are expected to be down 2-3% this year from last year, analysts say. The top eight diagnostics companies have an increasing percentage of the business. Hardest hit were immunoassay and clinical chemistry segments; best-performers were nucleic acid probes and diabetes care.